C4 Therapeutics Q3 2026 Results: Net Loss of $21.8M, Loss Narrows
C4 Therapeutics is a clinical-stage biopharmaceutical company focused on its TORPEDO platform and protein degrader candidates. As of October 30, 2026, the company had 131,317,488 shares of common stock outstanding and continues to incur significant losses to fund its research and development programs.
- Key figure
- Net loss $21.8M